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DEAR EDITOR, Lentigo maligna (LM) is a potential precursor
lesion of lentigo maligna melanoma (LMM). It is treated to
prevent progression to LMM. A recent epidemiological study
reports a progression rate of 20–26% over the course of
25 years.1 The gold standard treatment is surgical excision
with a 5-mm margin.2 Topical application of imiquimod
cream is an off-label alternative.2,3 Complete clinical response
rates for LM treated with imiquimod vary from 371% to
100%.4–6 We report three patients with LM who developed
lymphoedema following application of topical imiquimod.
Three consecutive patients with LM were treated according
to our protocol. Patients were instructed to apply imiquimod
once daily to the lesion with a 1- to 2-cm margin, for
12 weeks. The goal was to achieve at least 10 weeks of
inflammation. Depending on the inflammatory reaction, the
treatment schedule was adapted. If it was too intense, patients
were instructed to apply imiquimod three times per week, or
if the inflammation was insufficient, patients were instructed
to apply imiquimod 2–3 times daily.7
The first patient was a 66-year-old woman with a 9 9
10 mm pigmented brown macule on the left cheek. The
diagnosis of LM was confirmed by a punch biopsy. After
12 weeks of treatment with imiquimod 5%, no residual pig-
mentation was visible macroscopically or by dermatoscopy.
Within days after starting treatment, the patient developed
erythema, soreness and oedema at the site of application. The
erythema partially subsided, the soreness quickly disappeared,
but a nonpitting swelling persisted. A punch biopsy obtained
2 years post-treatment demonstrated fibrosis, with increased
numbers of fibroblasts and a mild lymphohistiocytic infiltrate
that had replaced the normal subcutaneous tissue (Fig. 1a, b).
D2-40 immunostaining showed several compressed lymphatic
vessels within this fibrotic tissue. Four years post-treatment,
the lymphoedema was still present.
The second patient was a 68-year-old woman with a 14 9
14-mm irregularly pigmented macule on her right cheek. LM
was confirmed histopathologically. She applied imiquimod
once daily during the first 4 weeks of treatment. As a result of
intense inflammation she was instructed to apply the imiqui-
mod three times weekly for the remaining 8 weeks, for a total
of 12 weeks. One month post-treatment a biopsy showed
postinflammatory hyperpigmentation; no LM was found. In
the dermis oedema was observed. Histologically it was unclear
if the oedema was lymphoedema or residual oedema because
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Fig 1. (a, b) Biopsy obtained from the left cheek, 2 years after treatment with imiquimod, demonstrating fibrosis and chronic inflammation.
Haematoxylin and eosin stain, original magnification 9 25 (a), 9 100 (b). (c) D2-40 immunostaining of compressed lymphatic vessels in fibrotic
tissue (original magnification 9 100).
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of inflammation. The oedema persisted for 3 years, after
which it disappeared.
The third patient was a 69-year-old woman, who was
referred following excision of a LMM on her right cheek. His-
tological examination of the excised lesion showed radically
excised LMM with a Breslow thickness of 06 mm. Several
years later, pigmentation measuring 15 9 15 mm appeared
around the scar. A biopsy showed LM, without evidence of
LMM. The patient declined surgical treatment because she
found the potential scarring unacceptable. She was treated
with off-label imiquimod. During treatment, the patient devel-
oped an inflammatory reaction with erythema, swelling, sore-
ness and crusting. After treatment, no residual pigmentation
was present. The erythema and soreness disappeared but lym-
phoedema persisted. The lymphoedema disappeared gradually
after a year.
Topical imiquimod is an off-label option for the treatment
of patients with LM who do not qualify for or do not opt for
surgical treatment. Imiquimod is applied for a prolonged per-
iod of time to achieve a sufficient inflammatory response.5
We hypothesize that lymphoedema may complicate treatment
of patients with LM using topical imiquimod. This adverse
effect may be caused by the intense treatment regimen used
in our patients, resulting in severe inflammation and signifi-
cant dermal fibrosis, impairing normal tissue drainage by
afferent lymphatic vessels.
In the two patients who had biopsies after imiquimod treat-
ment (2 years post-treatment for one and 1 month after for
the other), fibrosis was clearly present in the reticular dermis
histologically. We hypothesize that in our patients, similar to
the sequence of events during cutaneous wound healing, a late
phase of remodelling (maturation) may have followed previ-
ous phases of inflammation and proliferation in response to
imiquimod. The remodelling phase involves degradation of
excess collagen and organization of fibrotic connective tissue,
which may take several years.8 This may explain why lym-
phoedema persisted and only resolved in two of the three
patients. Alternatively, the lymphoedema may have been
related to other unknown or unrecognized factors.
In conclusion, topical imiquimod is an off-label alternative
treatment option for the treatment of LM, for patients who
are ineligible or do not opt for surgical treatment. When pre-
scribing topical imiquimod for a lesion located on the cheek
for a prolonged period of time, patients should be informed
about the risk of secondary lymphoedema.
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